BIO 2025: CDMO Partnerships in the Biologics Field

BioPharm International® spoke with Bartłomiej Czubek, director of Business Development at Poland-based contract development and manufacturing organization (CDMO) Mabion, about the types of partnerships that companies like his are currently engaging in and how both sides tailor what they offer to fit the needs of the other partner and of patients.

The conversation took place as Mabion participated in the Biotechnology Innovation Organization (BIO) International Convention in Boston from June 16–19, 2025.

“What really works is a mix of good planning, strong technology, and open communication with clients,” Czubek says in the interview. “For example, using isolators for sterile filling helps reduce the risk of contamination. At the same time, building an integrated process from cell line to final product helps save time and avoid delays. Another key point again, is flexibility. Every project is different, so having modular equipment, skilled teams, and the ability to adjust timelines or batch sizes makes a big difference. It's also very important to build strong relations with trusted suppliers for raw materials and reagents or services that a CDMO doesn't have in-house.”

Mabion is also using the occasion of BIO 2025 to announce a €500,000 (US$574,119) oncology services contest that will culminate at another conference, CPHI Frankfurt, Oct. 28–30, 2025 (1). The contest aims to help accelerate development of recombinant protein-based cancer therapies, with the winner receiving the monetary credit toward Mabion’s end-to-end CDMO services.

Mabion can be found at Booth #2445 at BIO 2025.

Click the above video to watch the full interview with Bartłomiej Czubek.

Click here for all of our BIO 2025 coverage.

*Scroll below for a full transcript of the video.

Reference

1. Mabion. Mabion Launches €500,000 Services Contest to Support Next-Gen Oncology Breakthroughs. Press Release. June 17, 2025.

About the speaker

Bartłomiej Czubek is director of Business Development, Mabion.

Transcript

Editor's note: This transcript is a direct, unedited rendering of the original audio/video content. It may contain errors, informal language, or omissions as spoken in the original recording.

My name is Bartłomiej Czubek and I'm a director of Business Development in Mabion. I have a background in biotechnology, and I've been with the company for over 12 years. I started my journey at Mabion as, specialist in selling development. later I led the analytical R&D team followed by managing our clinical research development.

When Mabion changed its strategy and became a CDMO, I took on the role of building our business development team. and today I'm responsible for managing partnerships, identifying trends in biotech industry, and preparing tailored proposal for our clients.

The biologic CDMO market is growing fast. There is high demand for advanced therapies like monoclonal and bispecific antibodies, cell and gene therapies and ADCs. CDMOs give biotech and pharma companies access to expert teams, modern technologies, flexible manufacturing and strong regulatory support, helping them bring products to market faster and at lower cost.

As the field moves forward, there are a key thing to know. first, flexibility is essential. drug pipelines are shifting and CDMOs need to adapt quickly, to new types of molecules and changing client's needs. Second, using the right technologies like single use systems, automation and digital tools, can speed up production and improve quality

Third, clients prefer working with partners who offer everything in one place, from development to commercial manufacturing with no, handoffs. finally, global reach and available capacity are more important than ever. as demands grows, CDMOs with strong infrastructure and global sites will be key partners.

Shrink top quality is essential, but today it's just one part of the equation. Steady drug manufacturers are also need to secure the supply chain, integrate service across the full development cycle, and deliver on time and within budget. this requires not only strong technical capabilities, but also smart planning and coordination.

today as titres are higher and biologics become more potent, flexibility is more important than ever. CDMOs must be able to quickly adapt to the specific needs of each client, both at the clinical and commercial stage, at Mabion we've built our capabilities to meet those needs from small batches to full scale production.

What really works is, a mix of good planning, strong technology, and open communication with clients. for example, using isolators for sterile filling helps reduce the risk of contamination at the same time. building an integrated process from cell line to final product helps save time and avoid delays.

Another key point again, is flexibility. Every project is different. so having modular equipment, skilled teams and the ability to adjust timelines or, batch sizes makes a big difference. it's also very important to build strong relations with trusted suppliers for raw materials and reagents or services, that a CDMO doesn't have in-house.

A reliable Network helps keep timelines on track and support smooth project delivery. At Mabion, we focus on bridging all this together. we control the full process and work closely with partners so we can respond fast when clients need it without losing quality or adding cost.

It won't be rather surprising. I'm looking forward to meeting potential partners and, clients who could benefit from working with Mabion. BIO International is a great place to connect, exchange ideas, and explore new collaborations. It's also a perfect opportunity to track market trends, understand what biotech companies are looking for, and show how our CDMO services can support the goals, from early development to commercial supply.